Knisely 2023 summarizes a November 7-8, 2022, workshop on “Mucosal Vaccines for SARS-CoV-2” hosted by NIAID, CEPI, BMGF, BARDA, and Wellcome Trust where participants developed seven key recommendations for the development of mucosal vaccines: 1) continue investment in SARS-CoV-2 mucosal vaccines research and development, 2) connect early-stage researchers with advanced development partners and de-risk candidates, 3) identify mucosal correlates of protection and develop standardized assays and sampling protocols, 4) develop animal models that are predictive of mucosal responses and transmission effects in humans, 5) develop and harmonize study protocols to assess impact on infection and transmission, 6) further research on optimal vaccine platforms, adjuvants, and administration routes, and 7) encourage regulators to align on authorization pathways.
Milestone
3.2.b
SARS-CoV-2 mucosal vaccine workshop
Completed
High priority
Publish the findings of a workshop on SARS-CoV-2 mucosal vaccines to identify gaps, challenges, and opportunities in mucosal approaches for vaccine development.